US FDA issues draft guidance on user fees and refunds for PMAs
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued draft guidance on the types of premarket approval applications that are subject to medical device user fees as well as those that do not have an associated user fee1,2. The document also identifies industry and FDA actions on these submissions that may result in a refund of the fee.